The Stanford 2024 ibogaine study
Magnesium-ibogaine therapy in 30 Special Operations veterans with TBI, published in Nature Medicine. The first peer-reviewed study of this scale on ibogaine in US veterans by a major academic medical center.
In January 2024, Stanford Medicine researchers published Magnesium-ibogaine therapy in veterans with traumatic brain injuries in Nature Medicine. The study followed 30 US Special Operations Forces veterans with histories of TBI and repeated blast exposure, almost all of whom had clinically significant psychiatric symptoms — PTSD, depression, anxiety — and functional impairments at baseline. The participants self-referred for treatment with magnesium and ibogaine at a clinic in Mexico; researchers followed them through pre-treatment, the treatment itself, and a one-month post-treatment evaluation.
Key findings
- Significant reductions in PTSD, depression, and anxiety symptoms at one-month follow-up — average reductions of 88%, 87%, and 81% respectively.
- Improvements in disability and functional measures.
- Cognitive improvements, particularly in executive function.
- Brain wave changes observed on EEG: veterans whose executive function improved tended to show increased theta-rhythm activity; veterans whose PTSD symptoms decreased showed reduced complexity in cortical activity patterns.
The magnesium protocol
The study used magnesium pre-treatment to mitigate cardiac risk — ibogaine prolongs the QT interval, and magnesium supplementation has emerged as a key safety intervention. This protocol is now adopted by reputable clinics. Lead author was Kirsten N. Cherian; corresponding author Nolan R. Williams.
What the study does and doesn’t establish
It’s an open-label observational study of self-referred patients, not a randomized controlled trial. The improvements are clinically meaningful and consistent with prior reports, but causation remains formally unestablished pending controlled studies. The significance is in part that this is the first peer-reviewed work of this scale on ibogaine in US veterans, conducted by a major academic medical center, in a top-tier medical journal — milestones that historically precede formal regulatory engagement.